Monte Rosa Therapeutics, Inc. (GLUE)

NMS – Real vaqt narxi. Valyuta: USD

16.20

+0.44 (2.79%)

Bozor ochiq: Aug 12, 2026, 11:54 AM EDT

15.76

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

06.08.2026

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.15 per share a year ago.

06.08.2026

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk and cardiometabolic syndrome in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 MODeFIRe-1 Phase 2 study of MRT-2359 activated, in combination with apalutamide in metastatic castration-resistant prostate cancer patients (mCRPC) with androgen receptor (AR) mutations Phase 2a/b clinical trial for VAV1-directed MGD MRT-6160 (DDY391) activated in participants with Sjögren's disease; study to be conducted by Novartis under global exclusive development and commercialization license agreement Strong balance sheet with cash, cash equivalents, restricted cash, and marketable securities of $626.0 million, expected to support operations into 2029 BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the second quarter ended June 30, 2026. “We're tremendously proud of our progress to date in 2026, defined by strong execution across our clinical-stage portfolio, with two Phase 2 trials activated and additional trials expected across our programs,” said Markus Warmuth, M.D.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Monte Rosa Therapeutics, Inc. (GLUE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Videolar

No Data

Press-relizlar

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Videolar

No Data

Press-relizlar

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Search stocks

Monte Rosa Therapeutics, Inc. (GLUE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Videolar

No Data

Press-relizlar

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Videolar

No Data

Press-relizlar

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates